JERUSALEM, Israel, July 21 OramedPharmaceuticals, Inc. (OTCBB: ORMP.OB) ( http://www.oramed.com), a developerof alternative drug delivery systems, today reported positive results from aPhase 2A study of its oral insulin capsule, ORMD-0801, on type 1 diabeticpatients. The completion of this study marks Oramed's first clinical trial onpatients with Type 1 Diabetes Mellitus, whereas, all Oramed's trials up todate have been conducted on type 2 diabetic patients. This study evaluatedsafety, tolerability, and food effects in type 1 diabetic patients.
Oramed's oral insulin capsule, (ORMD-0801), was well tolerated bypatients and no serious adverse events were observed. The insulin absorptionwas not affected when given before meal ingestion.
Oramed Chief Scientific Officer, Miriam Kidron, PhD., remarked, "Theseresults demonstrate that Oramed's oral insulin capsule had a good safetyprofile and was effective on patients with type 1 diabetes when taken priorto a meal."
Currently, Oramed is conducting its Phase 2B clinical trial in SouthAfrica, in which the company is evaluating the effects of ORMD-0801 on type 2diabetic patients.
About Oramed Pharmaceuticals
Oramed Pharmaceuticals is a technology pioneer in the field of oraldelivery solutions for drugs and vaccines presently delivered via injection.Oramed is seeking to revolutionize the treatment of diabetes through itspatented flagship product, an orally ingestible insulin capsule currently inphase 2 clinical trials. Established in 2006, Oramed's technology is based onover 25 years of research by top research scientists at Jerusalem's HadassahMedical Center. The Company's corporate and R&D headquarters are based inJerusalem.
For more information, please visit http://www.oramed.com
Some of the statements contained in this press release areforward-looking statements which involve known and unknown risks,uncertainties and other factors which may cause the actual results,performance or achievements of the company, or industry results, to bematerially different from any future results, performance or achievementsexpressed or implied by such forward looking statements, including the risksand uncertainties related to the progress, timing, cost, and results ofclinical trials and product development programs; difficulties or delays inobtaining regulatory approval for our product candidates; competition fromother pharmaceutical or biotechnology companies; and the company's ability toobtain additional funding required to conduct its research, development andcommercialization activities. Please refer to the company's filings with theSecurities and Exchange Commission for a comprehensive list of risk factorsthat could cause actual results, performance or achievements of the companyto differ materially from those expressed or implied in such forward lookingstatements. The company undertakes no obligation to update or revise anyforward-looking statements.Company and Investor Relation Contacts: Oramed Pharmaceuticals Tara Horn USA: +1-646-240-4193 Int'l: +972-54-334-318 Office: +972-2-566-0001 Email: [email protected]
SOURCE Oramed Pharmaceuticals Inc.